After customs duty cuts on 17 cancer drugs, India’s price regulator ordered MRPs revised to pass on benefits, but activists say tax relief alone won’t make costly patented therapies affordable.
Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results